We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s warning letters for 2019 once again targeted many familiar GMP failures, such as quality units that either lacked or failed to follow written procedures. Read More
The FDA hit RAM Pharma, a drug compounding and outsourcing firm, for numerous failures at its Idaho Falls facility, including repeat findings of microbial growth and lax air sampling. Read More
A drugmaker in the Czech Republic was listed on the EudraGMDP inspection database for serious deficiencies at its Prague facility including the presence of mold and dead insects. Read More